Portal de Periódicos da CAPES

Beta-adrenoceptor-blocking drugs: Current status and the significance of partial agonist activity

1983; Elsevier BV; Volume: 52; Issue: 2 Linguagem: Inglês

10.1016/0002-9149(83)90185-6

1879-1913

William J. Louis, John J. McNeil, B. Jarrott, B. Pharm, Olaf H. Drummer,

Analytical Methods in Pharmaceuticals

There is some evidence that partial agonism is an important property of beta-blocking drugs, and this property may be exploited to produce a new range of positive inotropic drugs. With the established beta-adrenoceptor-blocking drugs, the level of partial agonist activity is weak and the dose-response curve for this property is shallow. However, its absence appears to increase the likelihood of inducing bronchospasm and bradycardia, and drugs that lack intrinsic sympathomimetic activity appear more likely to be associated with rebound cardiac arrhythmias on cessation of treatment. The idea of a small level of hormone activity—in this case, catecholamine activity—being necessary to maintain normal cardiac and perhaps bronchial function is not new. Minimal doses of steroids are essential to maintaining the inotropic action of cardiac muscle. There is now enough accumulated evidence to suggest that a minimal degree of betaadrenoceptor stimulation is also important for normal bronchial and cardiac function, and its absence increases the incidence of bradycardia and the risks of bronchospasm and rebound arrhythmias.